Testing of Bevacizumab, Erlotinib, and Atezolizumab for Advanced-Stage Kidney Cancer
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib,
and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that
has spread to other places in the body (advanced). Bevacizumab is in a class of medications
called antiangiogenic agents. They work by stopping the formation of blood vessels that bring
oxygen and nutrients to tumors. This may slow the growth and spread of tumors. Erlotinib is
in a class of medications called kinase inhibitors. It works by blocking the action of a
protein called EGFR that signals cancer cells to multiply. This helps slow or stop the spread
of cancer cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the
body's immune system attack the cancer, and may interfere with the ability of tumor cells to
grow and spread. Combination therapy with bevacizumab, erlotinib, and atezolizumab may
stabilize or shrink advanced hereditary leiomyomatosis and kidney cancer.